Navigation Links
For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
Date:5/18/2009

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to treat the disease. In 2008, TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira accounted for 80 percent of rheumatoid arthritis drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative biologics such as Roche/Chugai's Actemra/RoActemra will take market share away from the TNF-alpha inhibitors as interviewed rheumatologists indicate they switch to one of these agents for patients who respond inadequately to two TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred agent for TNF-refractory patients and is forecasted to achieve sales of nearly $2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and is expected to take significant market share away from Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the indication following its recent approval for rheumatoid arthritis by the Food and Drug Administration. Additionally, an emerging agent from Pfizer is expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal patient share from the TNF-alpha inhibitors, in particular, and constrain the biologics market," said Decision Resources Analyst Joanna Kim, M.Ed. "The potential of this oral Jak-3 inhibitor was demonstrated by its impressive efficacy in a recent Phase II clinical study for rheumatoid arthritis."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes
2. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
3. Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
4. The future of personalized cancer treatment: An entirely new direction for RNAi delivery
5. An Aid to Tailoring Prostate Cancer Treatment
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
8. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
9. Can New Surgery Revolutionize Diabetes Treatment?
10. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
11. New Cancer Treatment Achieves First Mesothelioma Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has launched a residency ... to a residency in a United States hospital. Being accepted into a residency ... According to data released by the ECFMG®, every year, 50 percent of international ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the newest ... 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic ... skin cancer , and more. She graduated from the University of Florida College of ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and athletic trainers ... say researchers presenting their work at the American Orthopaedic Society for Sports ... evaluating the patterns of change in concussion symptom presentation, diagnostic tools used and ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid ... cancer that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens ... reoccurrence and relapse. With such a challenging diagnosis that requires immediate action, ...
(Date:7/20/2017)... PA (PRWEB) , ... July 20, 2017 , ... For ... of utmost importance. The adjustable beds used in such facilities are specially designed to ... feature adequate arm support. , An inventor from Rochester, Ind., has invented the ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 11, 2017  Bayer has awarded grants totaling more than ... of its prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. ... Philadelphia and Uniformed Services University of the Health ... winners. Grant recipients were announced last night during a reception ... Congress, Berlin, Germany . ...
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
Breaking Medicine Technology: